<DOC>
	<DOCNO>NCT01415128</DOCNO>
	<brief_summary>This study compare pharmacokinetics omeprazole , rosiglitazone desipramine administer single oral dose avanafil healthy male subject .</brief_summary>
	<brief_title>Compare Pharmacokinetics Omeprazole , Rosiglitazone , Desipramine When Administered With Avanafil Healthy Male Subjects</brief_title>
	<detailed_description>There three cohort Phase I , single-center , open-label , crossover study : Cohort A ( omeprazole ) : This open-label , non-randomized , one-sequence crossover study design , 20 healthy male subject enrol administer single oral dose 40 mg omeprazole daily 8 day ( Days 1-8 ) plus single oral dose 200 mg avanafil Day 8 . On Days 7 8 , avanafil and/or omeprazole dos administer follow overnight fast least 10 hour . All subject confine Clinical Research Unit day prior omeprazole administration Day 7 remain confine approximately 13 hour follow dose Day 8 . Blood sample determination plasma omeprazole concentration obtain subject 0 ( 10 minute pre-dose ) , 20 , 40 minute 1 , 1.5 , 2 , 2.5 , 3 , 4 , 6 , 8 , 10 12 hour post-dose Days 7 8 . Pre-dose blood sample determination omeprazole also take morning Days 5-6 . Cohort B ( rosiglitazone ) : This randomize , open-label , two-period crossover study design , 20 male subject randomize receive follow treatment : - Treatment A : single oral dose 8 mg rosiglitazone follow overnight fast least 10 hour . - Treatment B : single oral dose 8 mg rosiglitazone plus single oral dose 200 mg avanafil follow overnight fast least 10 hour . The two treatment cohort separate washout period least 7 day . All subject confine Clinical Research Unit approximately morning Day -1 morning Day 2 treatment period . Blood sample determination plasma rosiglitazone concentration obtain subject 0 ( 10 minute pre-dose ) 0.25 , 0.5 , 0.75 , 1 , 2 , 4 , 6 , 8 , 10 , 12 , 16 24 hour post-dose . Cohort C ( desipramine ) : This randomize , open-label , two-period , crossover study design , 20subjects identify CYP2D6 extensive metabolizers ( determined genotyping ) randomize receive follow treatment : - Treatment A : single oral dose 50 mg desipramine follow overnight fast least 10 hour . - Treatment B : single oral dose 50 mg desipramine plus single oral dose 200 mg avanafil follow overnight fast least 10 hour . The avanafil dose administer 2 hour desipramine administration . The two treatment cohort separate washout period least 10 day . All subject confine Clinical Research Unit morning Day -1 morning Day 2 treatment period . Blood sample determination plasma desipramine concentration obtain subject 0 ( 10 minute pre-dose ) 1 , 2 , 4 , 6 , 8 , 10 , 12 , 24 , 48 , 72 96 hour post-dose . Subjects visit study site outpatient morning remain PK blood sample collection Days 3-5 .</detailed_description>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Desipramine</mesh_term>
	<criteria>1 . Voluntarily consent participate study ( informed consent form must sign date prior study related assessment ) . 2 . Adult male subject 18 45 year age inclusive . 3 . A body weight least 50 kg body mass index ( BMI ) 18 30 kg/m2 , inclusive [ BMI calculate weight kg/ ( height ) 2 ] . 4 . Subjects must identify CYP2D6 extensive metabolizers ( determined genotyping ) Cohort C 5 . Subjects able communicate investigator , understand comply requirement study participation . 6 . Medically healthy , clinically significant screen result ( e.g. , laboratory profile , medical history , ECGs , physical exam , etc . ) , opinion investigator consultation Sponsor . 7 . Male subject willing use condom spermicide sexual activity 90 day last dosing avanafil willing donate sperm 90 day dose . 1 . A history presence significant cardiovascular ( include thromboembolic disorder ) , neurological , hematological , psychiatric , hepatic , gastrointestinal , pulmonary , endocrine , immunologic renal disease condition know interfere absorption , distribution , metabolism , excretion drug place subject increase risk determine investigator . 2 . Any clinically significant laboratory abnormality judge investigator . Inclusion subject normal range laboratory value must approve VIVUS prior subject enrollment . 3 . A predisposition priapism , subject sickle cell disease blood dyscrasia . 4 . Known history cardiovascular cerebrovascular event , history angina . 5 . History ECG evidence highrisk arrhythmia ECG judge investigator clinically significant . 6 . Hypertrophic obstructive clinically significant cardiomyopathy , moderate severe cardiac valvular disease . 7 . Subjects whose pulse low 50 bpm screen 50 bpm prior dose period 1 . 8 . Acute illness , especially infection , within 2 week dose . 9 . Systolic blood pressure &lt; 90 &gt; 140 mmHg ; diastolic blood pressure &lt; 60 &gt; 95 mmHg screen Day 1 ( 2 rechecks allow ) period 1 . 10 . History retinitis pigmentosa nonarteritic anterior ischemic optic neuropathy . 11 . Hemoglobin &lt; 12.0 g/dL . 12 . Subjects liver function test &gt; 1.5 ULN 13 . Positive urine drug test and/or positive urine alcohol test screen Day 1 . 14 . Positive test human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( HCV ) screening . 15 . Any history presence alcoholism drug substance abuse within 18 month define investigator . 16 . Allergy previously significant adverse event PDE5 inhibitor , omeprzole , rosiglitazone desipramine constituent . 17 . Use prescription overthecounter ( OTC ) medication , include herbal product , within 30 day prior Day 1 . Up 2 g per day acetaminophen allow discretion Investigator . 18 . Use drug Appendix 1 ( drug know clinical significance inhibit induce liver enzyme involve drug metabolism [ CYP P450 ] ) within 30 day prior Day 1 . 19 . Blood donation significant blood loss within 56 day prior Day 1 . 20 . Plasma donation within 14 day prior Day 1 . 21 . Any use tobacco nicotine product within 6 month prior Day 1 . 22 . Any subject receive investigational drug within 30 day six halflives , whichever longer , prior Day 1 . 23 . Evidence clinically significant medical , psychiatric , social condition history , physical examination laboratory study , opinion investigator , would contraindicate administration study medication , affect compliance , interfere study evaluation , limit study participation , confound interpretation study result . 24 . Involvement plan conduct study ( applies VIVUS designee staff , staff investigational site ) .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>